Inderm

Erythromycin, the active ingredient in Inderm, is a macrolide antibiotic presented as a topical formulation for skin use. It treats acne vulgaris and other superficial bacterial skin infections in patients who require localized therapy.

GNH USA supplies Inderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inderm, a topical macrolide antibiotic, is employed to manage bacterial skin conditions.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the face and trunk. Impetigo: eradicates Staphylococcus aureus or Streptococcus pyogenes causing superficial crusted lesions. Folliculitis: clears infected hair follicles and alleviates associated redness and pustules.

Topical erythromycin may cause local adverse reactions, ranging from mild irritation to rare severe events.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Pruritus (itching) localized to treated area. - Redness or erythema. - Dryness or peeling of the skin. - Contact dermatitis. - Mild scaling.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe photosensitivity leading to blistering. - Systemic absorption causing hepatic dysfunction (rare). - Severe ulceration or necrosis of skin. - Persistent or worsening infection indicating resistance.

Before using Inderm, consider the following safety measures.

Pregnancy Category B: use only if the potential benefit justifies the potential risk. Breastfeeding: caution advised; monitor infant for adverse effects. Known hypersensitivity to erythromycin or other macrolides: avoid use. Application on broken or inflamed skin may increase systemic absorption; limit use. Concurrent use with other topical antibiotics may promote resistance; avoid combination unless directed. Store at room temperature: keep in the original container, protect from moisture and light.

Topical erythromycin can interact with other agents, affecting safety or efficacy.

Major Interactions (Avoid): - Concurrent use with other macrolide antibiotics may increase systemic exposure. - Combined topical clindamycin may heighten risk of bacterial resistance.

Moderate Interactions (Monitor Closely): - Use with photosensitising agents (e.g., retinoids) may increase sunburn risk. - Application alongside other skin irritants can exacerbate local reactions. - Systemic absorption in extensive use may interact with warfarin; monitor INR if applicable.